Trial Profile
A Multicenter, Randomized, Double-Blind, Parallel Group, Two-Dose Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Velaglucerase alfa (Primary)
- Indications Gaucher's disease type I
- Focus Therapeutic Use
- Sponsors Shire
- 14 Nov 2014 New trial record